Synthetic Biology Healthcare Applications Market is expected to reach USD 21.9 billion by 2031

Synthetic Biology Healthcare Applications Market Trends & Forecast

According to a research study published by Knowledge Sourcing Intelligence (KSI), the synthetic biology healthcare applications market will expand from USD 13.1 billion in 2026 to USD 21.9 billion in 2031 at a CAGR of 10.8% during the forecast period.

Synthetic biology healthcare applications use the engineered biological systems, cells, proteins, and gene circuits to create programmable therapeutic and/or diagnostic solutions. The healthcare applications in this sector are increasingly associated with protein engineering, synthetic genomes, RNA medicines, microbial therapeutics, and precision cellular therapies that are automated using artificial intelligence (AI) technologies. According to the OECD's 2025 "Synthetic Biology, AI, and Automation" assessment, healthcare is expected to have the largest impact of all deployment sectors, due primarily to advances in large language models, automation, robotics, and biological design integration. The FDA’s 2025 approvals of biologics and breakthrough therapies demonstrate continued progress toward accelerating the commercialisation of engineered biologics and gene-based medicines. Moreover, NIH-provided protein-engineering initiatives are increasing the ability to individualise or personalise therapeutic solutions for rare illnesses, oncology, and regenerative medicine applications.

Request a free sample copy or view the report summary: Synthetic Biology Healthcare Applications Market Report

Synthetic Biology Healthcare Applications Market Report Highlights

• FDA approved 46 novel drugs during 2025, strengthening commercialisation opportunities for synthetic biology-derived biologics and precision therapeutics.

• OECD’s 2025 assessment identified AI, robotics, and automation as core accelerators for synthetic biology healthcare innovation ecosystems.

• NIH-supported protein engineering research expanded programmable therapeutic design capabilities for advanced precision medicine development pipelines.

• FDA accelerated approval frameworks increasingly support the commercialisation of biologics, engineered cell therapies, and personalised genomic medicines.

Synthetic Biology Healthcare Applications Market Growth Drivers and Restraints

Growth Drivers:

• The acceleration of therapeutic discovery through the integration of AI with synthetic biology platforms, and the scaling of biological engineering by the use of synthetic biology platforms, has greatly improved the efficiency of therapeutic discovery and scalability. According to the OECD's December 2025 report on the state of synthetic biology, as synthetic biology continues to merge with large language models, robotics, and automated systems for experimentation, innovation within healthcare applications will be further accelerated. These AI-based systems will optimize the molecular prediction, protein folding analysis, metabolic engineering, and simulation of biological pathways, significantly decreasing the number of times that lab experiments will need to be repeated. Initiatives funded by the NIH for the development of programmable proteins are also proving how the programmable development of proteins enhances the specificity with which the proteins can find their intended targets and provides greater precision in the molecular customizing of proteins, thus providing better results through the use of precision medicine. An analysis of the AI-focused portfolio of NIH-funded biomedical research completed by the NIH showed that 15.9% of the NIH-funded research projects included AI technologies, and that there was also a corresponding 13.4% funding premium associated with AI-based research projects. The increasing convergence of computational and biological systems will continue to accelerate the development of synthetic biologics, engineered immune therapeutics, and next-generation RNA therapeutics.

• Regulatory modernisation and faster approval of biologics by governmental authorities are major contributors to the continued expansion of the market for synthetic biology-based applications (e.g., healthcare applications) that are classified as "biologics." According to the FDA, there were 46 novel approvals for drugs identifying biopharmaceuticals (biologics) approved for biopharmaceutical use in 2025, and new mechanisms for creating an expanded breakthrough therapy and an expedited approval pathway that will allow for the approval of more advanced therapeutic modalities. In addition, the FDA also indicated and/or implemented an expanded flexibility for approving personalised therapies and advanced therapies for rare genetically-based diseases, where large-scale, traditional clinical trials will not be required for many advanced therapies. FDA-related efforts to implement changes necessary to accelerate the approval of biosimilars and expand the ability of companies that manufacture advanced biologics will enhance the ability for products developed by synthetic biology to enter the market faster and at lower costs. Examples of such products include the regenerative product, Axogen's Avance Nerve Graft, and the continued creation and approval of biopharmaceutical products that have been engineered biologically, and thus will provide additional credibility for the regulatory authority to accept as an eligible candidate for commercialisation by the engineered biological product manufacturers that produce these products. The developments cited above will positively impact confidence in investment.

Restraints:

• Despite technological advancement, biosafety governance, manufacturing standardisation, and regulatory oversight remain significant barriers. OECD’s 2025 assessment highlighted increasing concerns regarding biosecurity risks, AI-enabled biological misuse, data governance vulnerabilities, and human oversight limitations associated with synthetic biology systems. Additionally, advanced biologics manufacturing requires highly controlled validation environments, increasing production complexity and commercialisation costs for healthcare applications.

Synthetic Biology Healthcare Applications Market Key Development

• January 2026: bit.bio, a next-generation human cell programming player located in Cambridge, has successfully closed its Series C funding round of $50 million with the lead investor M&G Investments.

• June 2025: Antheia has secured $56 million through a Series C funding round to further develop its synthetic biology platform, a system that utilizes genetically modified yeast to manufacture key drug components, hence making it possible for the company to address the persistent worldwide drug shortage issues.

• In January 2026, Ginkgo partnered with NVIDIA to integrate generative AI models into automated biological design and protein engineering workflows.

• In March 2026, the company launched Ginkgo Cloud Lab, enabling remote autonomous experimentation for biotechnology and therapeutic R&D.

Synthetic Biology Healthcare Applications Market Segmentation

Knowledge Sourcing Intelligence has segmented the Synthetic Biology Healthcare Applications Market based on product type, end user, application, and region:

Synthetic Biology Healthcare Applications Market, By Product Type

• Enzymes

• Synthetic DNA & RNA

• Chassis Organisms

• Xeno-nucleic Acids (XNA)

• Others

Synthetic Biology Healthcare Applications Market By End User

• Pharmaceutical & Biotechnology Companies

• Academic & Research Institutes

• Contract Research Organisations (CROs)

• Hospitals & Clinics

• Others

Synthetic Biology Healthcare Applications Market, By Application

• Drug Discovery & Development

• Diagnostics

• Vaccine Development

• Regenerative Medicine

• Gene & Cell Therapy

• Others

Synthetic Biology Healthcare Applications Market, By Region

• North America

  • USA

  • Canada

  • Mexico

• Europe

  • United Kingdom

  • Germany

  • France

  • Spain

  • Others

• Asia Pacific

  • China

  • India

  • Japan

  • South Korea

  • Indonesia

  • Thailand

  • Others

• South America

  • Brazil

  • Argentina

  • Others

• Middle East and Africa (MEA)

  • Saudi Arabia

  • UAE

  • Others

Synthetic Biology Healthcare Applications Market Key Players

• Ginkgo Bioworks

• GenScript Biotech

• Thermo Fisher Scientific

• Illumina

• Danaher Corporation

• AbCellera Biologics

• Precigen

• Poseida Therapeutics

• Mammoth Biosciences

• Codexis